

# **Punjab Chemicals and Crop Protection Limited (Revised)**

December 26, 2023

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Long Term Bank Facilities	35.02	CARE BBB+; Stable	Reaffirmed
Long Term / Short Term Bank Facilities	60.00 (Enhanced from 20.00)	CARE BBB+; Stable / CARE A2	Reaffirmed
Short Term Bank Facilities	30.00	CARE A2	Reaffirmed

Details of instruments/facilities in Annexure-1.

### Rationale and key rating drivers

The reaffirmation of the ratings on the bank facilities of Punjab Chemicals and Crop Protection Limited (PCCPL) considers PCCPL's healthy financial risk profile, extensive experience of the promoters and medium-term revenue visibility supported by offtake arrangements with its customers.

The rating strengths, however, are offset by revenue and customer concentration risk, exposure to risks intrinsic in agrochemical sector, susceptibility of margins to volatility in raw material prices and foreign exchange fluctuations.

#### Rating sensitivities: Factors likely to lead to rating actions

#### **Positive factors**

- Significant increase in revenue and PBILDT resulting in net cash accruals over ₹100 crore on sustained basis
- Improvement in capital structure marked by TOL/TNW below unity on sustained basis

#### **Negative factors**

- Decline in turnover coupled with lower-than-envisaged PBILDT margins, resulting in dip in net cash accruals below ₹75 crore on sustained basis
- · Higher-than-envisaged debt-funded capex resulting in weakening of financial risk profile and liquidity

### Analytical approach: Consolidated

CARE Ratings Limited (CARE Ratings) has considered the business and financial risk profiles of PCCPL in consolidation with SD AgChem (Europe) NV (SDAC), Belgium, the wholly owned overseas subsidiary company. SDAC, is the marketing arm of the group in Europe with various registrations for immediate supply of the company's products in the region.

### **Outlook: Stable**

Stable outlook reflects the company's ability to maintain its healthy financial risk profile amidst steady cash flow generation and absence of large debt-funded capital expenditure (capex).

## Detailed description of the key rating drivers:

## Key rating strengths

#### Healthy financial risk profile despite headwinds in FY23

PCCPL's total operating income (TOI) improved by around 7% during FY23 (refers to period April 1 to March 31) impacted by high channel inventory and pricing- pressure in key overseas markets coupled with erratic weather conditions in the domestic market. PBILDT margin declined by 300 bps as a result of higher raw material and energy costs. Nevertheless, PCCPL's financial risk profile remained healthy. The capital structure continues to remain comfortable with tangible net worth of ₹279.88 crore as on March 31, 2023 (₹224.74 crore as on March 31, 2022) and overall gearing of 0.34x as on March 31, 2023 (0.42x as on March 31, 2022). The capital structure is likely to remain comfortable in the near term as no large debt-funded capex is envisaged.

<sup>&</sup>lt;sup>1</sup>Complete definition of the ratings assigned are available at <a href="https://www.careedge.in">www.careedge.in</a> and other CARE Ratings Ltd.'s publications



Interest coverage ratio, though declined, remained satisfactory at 6.69x in FY23 (11.35x in FY22). Total debt to gross cash accruals remained satisfactory at 1.15x in FY23 (0.92x in FY22).

During H1FY24 (Unaudited; refers to period April 1 to September 30), PCCPL achieved TOI of ₹525.35 crore (₹552.57 crore in H1FY23) and PAT of ₹39.98 crore (₹37.84 crore in H1FY23). CARE Ratings expects the performance of the company to improve and financial risk profile to remain healthy over the medium term.

#### **Experienced promoters and professional management**

The company has a track record of more than four decades in manufacturing of crop protection products. Shalil Shroff (Managing Director), the second-generation promoter has an experience of over three decades in the chemical industry. Mukesh Patel (Chairman) is experienced in finance and corporate management for more than four decades. The promoter is supported by a qualified team of professionals, Vinod Kumar Gupta (Chief Executive Officer, CEO), a Chemical Engineer, has more than 24 years' experience in operations management in large petrochemicals and oleochemicals sector. Ashish Nayak, (CFO), has over 15 years of experience in the chemical industry. CARE Ratings believes that the company will continue to benefit from the experienced promoters and professional management.

#### Medium-term revenue visibility

PCCPL has arrangements with multinational companies under contract research and manufacturing services (CRAMS) business model which is based on cost-plus pricing mechanism. The contract has a tenor of five years and most of these agreements get auto renewed, providing medium-term revenue visibility for the company. Also, product registration challenges like long tenor, high cost etc, at customers' end, increases probability of contract renewal by the clients to a large extent. PCCPL has a product pipeline across segments at different stages of development. Timely commercialization of these products may further improve PCCPL's business risk profile.

#### Key rating weaknesses

#### Revenue and client concentration risk

Top five products driving revenue of PCCPL contributed around 60% (PY: 40%) of the total sales in FY23. Furthermore, the top five customers contributed nearly 65% to total operating income in FY23 (72% in FY22). In addition, major sales to single foreign market, Europe also exposes PCCPL's business to geographical concentration risk. Notwithstanding expansion in the existing product line, addition of new molecules and new clientele is expected to dilute the concentration risk gradually in the coming years.

#### **Exposure to risks intrinsic in agrochemical sector**

The crop-protection sector remains susceptible to various environmental rules and regulations in different countries. The sector is highly dependent on farm income and monsoon levels. Various licenses, environmental clearances and registrations are mandatory for the setting up of a manufacturing facility and selling its products which involves high-cost outflow and long tenor. Hence, infringement of any of the laws and any significant adverse change in the regulatory policies or distribution of monsoon may have significant impact on PCCPL's revenues.

### Susceptibility to volatility in raw material prices and forex fluctuation risk

Around 60-65% of the operating cost of the company consists of raw material expenses. Rapid changes in the base chemicals market with significant adjustments to the global demand and supply chain creates a volatile environment which exposes consumers like PCCPL to the volatility in raw material prices. Around 22-25% of its major raw materials requirements are met through imports, hence is exposed to foreign exchange fluctuation risk as well. The forex risk is partly covered by natural hedge, PCCPL being net exporter (around 58% of sales). The major export destinations are Europe, Japan, Israel, USA and Latin America.

#### **Liquidity: Adequate**

The liquidity profile of PCCPL is characterized by sufficient cushion in accruals vis-à-vis repayment obligations. The cash flows from operations in FY24 are expected to adequately cover the external repayment obligations of around ₹8 crore. The average of maximum monthly utilisation remained at 94% for the past 12 months through June 30, 2023. However, the average utilisation stands at 67% for the same period. Also, the company enjoys working capital demand loan which is minimally utilised. The cash credit limit has been enhanced during Q1FY24 to fund the increasing working capital requirements.



Assumptions/Covenants: Not applicable

Environment, social, and governance (ESG) risks: Not applicable

### **Applicable criteria**

Policy on default recognition

Consolidation

Financial Ratios - Non financial Sector

Liquidity Analysis of Non-financial sector entities

Rating Outlook and Credit Watch

**Short Term Instruments** 

**Manufacturing Companies** 

**Pesticide** 

**Industry classification** 

Macro Economic Indicator	Sector	Industry	Basic Industry
Commodities	Chemicals	Fertilizers & Agrochemicals	Pesticides & Agrochemicals

Incorporated in November 1975, PCCPL was promoted by S.D. Shroff in association with Excel Industries Ltd and Punjab State Industrial Development Corporation (PSIDC) in the name of Punjab United Pesticides & Chemicals Limited (PUPCL), a public limited company. Later, in March 2006, the name of the company was changed to PCCPL with all its divisions – agrochemicals, pharmaceuticals, intermediates, chemicals & international trading, under one umbrella. The company specialises in agrochemicals which are key revenue driver for the company (70-80%). It is into CRAMS largely for agrochemicals. CRAMS accounted approximately 60-70% of the revenue over the years.

Brief Financials (₹ crore) - Consolidated	March 31, 2022 (A)	March 31, 2023 (A)	H1FY24 (UA)
Total operating income	933.46	1003.55	525.35
PBILDT	140.02	120.54	75.03
PAT	83.46	61.10	39.98
Overall gearing (times)	0.42	0.34	0.32
Interest coverage (times)	11.35	6.69	7.39

A: Audited UA: Unaudited; Note: 'the above results are latest financial results available'

Brief Financials (₹ crore) - Standalone	March 31, 2022 (A)	March 31, 2023 (A)	H1FY24 (UA)
Total operating income	930.57	1,001.28	523.24
PBILDT	138.69	119.74	74.13
PAT	80.82	60.94	39.44
Overall gearing (times)	0.39	0.32	0.30
Interest coverage (times)	11.57	6.89	7.39

A: Audited UA: Unaudited; Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not applicable



Any other information: Not applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

**List of Subsidiaries and Associates:** Annexure 6

#### **Annexure-1: Details of facilities**

Name of the Instrument	ISIN	Date of Issuance	Coupon Rate (%)	Maturity Date	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Term Loan		-	-	December 2027	35.02	CARE BBB+; Stable
LT/ST Fund- based/Non- fund-based- EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLC		-	-	-	60.00	CARE BBB+; Stable / CARE A2
Non-fund- based - ST- Letter of credit		-	-	-	30.00	CARE A2

# Annexure-2: Rating history for the last three years

		Current Ratings			Rating History			
Sr. No.	Name of the Instrument/Bank Facilities	Туре	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022- 2023	Date(s) and Rating(s) assigned in 2021- 2022	Date(s) and Rating(s) assigned in 2020- 2021
1	Fund-based - LT- Term Loan	LΤ	35.02	CARE BBB+; Stable	1)CARE BBB+; Stable (06-Sep-23)	1)CARE BBB+; Stable (30-Aug- 22)	1)CARE BBB+; Stable (23-Nov- 21) 2)CARE BBB; Stable (06-Apr- 21)	1)CARE BBB-; Stable (22-Jun- 20) 2)CARE BBB-; Stable (03-Jun- 20)
2	LT/ST Fund- based/Non-fund-	LT/ST*	60.00	CARE BBB+;	1)CARE BBB+;	1)CARE BBB+;	1)CARE BBB+;	1)CARE BBB-;



1					0.11.	0.11.7	0.11.7	G: 11 /	0. 11 /
		based-EPC / PCFC /			Stable /	Stable /	Stable /	Stable /	Stable /
		FBP / FBD / WCDL /			CARE	CARE A2	CARE A2	CARE A2	CARE A3
		OD / BG / SBLC			A2	(06-Sep-23)	(30-Aug-	(23-Nov-	(22-Jun-
							22)	21)	20)
								2)CARE BBB; Stable / CARE A3+ (06-Apr- 21)	2)CARE BBB-; Stable / CARE A3 (03-Jun- 20)
	3	Non-fund-based - ST-Loan Equivalent Risk	ST	-	-	1)Withdrawn (06-Sep-23)	1)CARE A2 (30-Aug- 22)	1)CARE A2 (23-Nov- 21) 2)CARE A3+ (06-Apr- 21)	1)CARE A3 (22-Jun- 20) 2)CARE A3 (03-Jun- 20)
	4	Non-fund-based - ST-Letter of credit	ST	30.00	CARE A2	1)CARE A2 (06-Sep-23)	1)CARE A2 (30-Aug- 22)	1)CARE A2 (23-Nov- 21)	-

<sup>\*</sup>Long term/Short term.

# Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not applicable

## **Annexure-4: Complexity level of the various instruments rated**

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	LT/ST Fund-based/Non-fund-based-EPC / PCFC / FBP / FBD / WCDL / OD / BG / SBLC	Simple
3	Non-fund-based - ST-Letter of credit	Simple

#### **Annexure-5: Lender details**

To view the lender wise details of bank facilities please <u>click here</u>

# **Annexure – 6: List of Subsidiaries and Associates**

Subsidiary	Country of Incorporation	% of shareholding
SD AgChem (Europe) NV	Belgium	100%

**Note on the complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.



#### Contact us

#### Media Contact

Mradul Mishra Director

**CARE Ratings Limited** Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

#### **Relationship Contact**

Ankur Sachdeva Senior Director

CARE Ratings Limited Phone: 91 22 6754 3444

E-mail: Ankur.sachdeva@careedge.in

#### **Analytical Contacts**

Akhil Goyal Director

CARE Ratings Limited
Phone: +91 - 22-6754 3590
E-mail: akhil.goyal@careedge.in

Ashish Kashalkar Assistant Director **CARE Ratings Limited** Phone: 9102040009009

E-mail: Ashish.Kashalkar@careedge.in

Sachita More Lead Analyst

**CARE Ratings Limited** 

E-mail: Sachita.More@careedge.in

#### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

#### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information, please visit <a href="https://www.careedge.in">www.careedge.in</a>